Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate

BMC Medicine
F D Richard HobbsSimon Capewell

Abstract

The most prescribed medications in the world are statins, lipid modifiers that have been available for over 25 years and amongst the most investigated of all drug classes. With over a million patient years of trial data and publications in the most prestigious medical journals, it is remarkable that quite so much debate remains as to their place in healthcare. They have had a bittersweet passage, with vocal concerns over their possible risks, from suicide to cancer, and allegations that they do not work in women or the elderly, to statements that the whole published dataset, on over 200,000 patients consenting to enter trials, was fatally compromised by being industry-funded by and large. On the other side, there have been billions of dollars spent on generating their evidence base followed by promotion which has returned that investment many times over in profits, and a powerful scientific lobby that argue they are wonder drugs and that continued nihilism on their value risks patient lives. So who is right?

References

Jun 6, 2006·Journal of the American College of Cardiology·Benjamin M SciricaUNKNOWN PROVE IT-TIMI 22 Investigators
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Aug 26, 2009·Bulletin of the World Health Organization·Gerd Gigerenzer
Jun 18, 2010·Cardiovascular Therapeutics·Subrata Chakrabarti, Jane E Freedman
Aug 13, 2010·The Annals of Pharmacotherapy·Devin M MannIan Kronish
Oct 11, 2011·Journal of the American College of Cardiology·Ki Hong LeeUNKNOWN KAMIR (Korea Acute Myocardial Infarction Registry) Investigators
May 23, 2012·Progress in Lipid Research·Aneta Otocka-KmiecikMaciej Banach
Jun 13, 2012·Archives of Internal Medicine·Beatrice A GolombHalbert L White
Oct 12, 2012·Archives of Medical Science : AMS·Manfredi RizzoDimitri P Mikhailidis
Jan 3, 2013·Current Pharmaceutical Design·Maciej BanachAgnieszka Dobrzyn
Jan 16, 2013·Current Pharmaceutical Design·Niki KatsikiManfredi Rizzo
Feb 26, 2013·The New England Journal of Medicine·Ramón EstruchUNKNOWN PREDIMED Study Investigators
Oct 24, 2013·BMJ : British Medical Journal·John D AbramsonJames M Wright
Feb 28, 2014·International Urology and Nephrology·Maciej BanachAdrian Covic
Apr 29, 2014·European Journal of Preventive Cardiology·Beatrice A Golomb
Jun 4, 2014·The American Journal of the Medical Sciences·Christopher M GamboaPaul Muntner
Jun 19, 2014·Journal of Cardiovascular Pharmacology and Therapeutics·Simona DraganMaciej Banach
Feb 18, 2015·European Journal of Preventive Cardiology·Kornelia KotsevaUNKNOWN on behalf of the EUROASPIRE Investigators
Mar 17, 2015·The New England Journal of Medicine·Jennifer G RobinsonUNKNOWN ODYSSEY LONG TERM Investigators
Mar 31, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Maciej BanachAdrian Covic
Apr 11, 2015·Archives of Medical Science : AMS·Maciej BanachDimitri P Mikhailidis
Apr 25, 2015·Expert Opinion on Drug Safety·Maciej BanachDimitri P Mikhailidis
May 29, 2015·Thrombosis and Haemostasis·Amirhossein SahebkarUNKNOWN Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Jun 16, 2015·Atherosclerosis·Amirhossein SahebkarUNKNOWN Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
Jul 21, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Maciej BanachUNKNOWN Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
Sep 20, 2015·BMC Medicine·Maciej BanachUNKNOWN Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
Dec 4, 2015·Thrombosis and Haemostasis·Amirhossein SahebkarUNKNOWN Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group

❮ Previous
Next ❯

Citations

Apr 1, 2016·Journal of Cachexia, Sarcopenia and Muscle·Maciej Banach, Maria-Corina Serban
Jun 22, 2016·Nutrition·Amirhossein SahebkarMaciej Banach
Jun 3, 2016·Expert Opinion on Pharmacotherapy·Jaideep PatelMaciej Banach
Jun 29, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Maciej BanachUNKNOWN Lipid Blood Pressure Meta-analysis Collaboration Group
Jan 24, 2017·Drug Discovery Today·Amir Abbas MomtaziAmirhossein Sahebkar
Jan 29, 2017·Expert Opinion on Pharmacotherapy·Yogita RochlaniWilbert S Aronow
Mar 8, 2017·Current Opinion in Cardiology·Vanessa BianconiMatteo Pirro
Jan 10, 2017·Expert Opinion on Investigational Drugs·Peter PensonMaciej Banach
Jan 11, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Peter P TothMaciej Banach
Apr 20, 2018·Expert Opinion on Investigational Drugs·Serban M MaiereanMaciej Banach
Jan 18, 2018·Expert Opinion on Drug Safety·Arrigo F G Cicero, Alessandro Colletti
Jun 21, 2017·Journal of Cachexia, Sarcopenia and Muscle·Amirhossein Sahebkar, Maciej Banach
Nov 30, 2016·Journal of Cachexia, Sarcopenia and Muscle·Amirhossein SahebkarMaciej Banach
Feb 23, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Niki KatsikiUNKNOWN International Lipid Expert Panel (ILEP)
May 28, 2021·Atherosclerosis·Amir Vahedian-AzimiAmirhossein Sahebkar

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Related Papers

Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
V Rusu
Climacteric : the Journal of the International Menopause Society
Robert Cheifitz
Nature Reviews. Gastroenterology & Hepatology
Jaume Bosch, Xavier Forns
© 2022 Meta ULC. All rights reserved